Currently, there are many shortcomings in disease detection methods, which often require invasive procedures, can be lengthy and expensive, and may discourage or delay individuals from undergoing testing, resulting in late detection of health issues that may be too advanced to treat effectively. In light of this, Qi Diagnostics aims to utilize a simple and convenient breath test to make testing more accessible and encourage proactive health monitoring, with the goal of achieving earlier diagnosis and treatment of health issues. We expertise in the development and manufacturing of proprietary Volatile Organic Compound (VOC) nano sensor-based in vitro diagnostic and screening devices. The patented sensor technologies have high specificity properties to single targeted gas, which makes it clinical level for detecting specific biomarkers.

Qi Diagnostics’ flagship project is the development of a non-invasive breath test instrument for detecting lung cancer. Compared to traditional lung CT and X-ray examinations, using breath testing methods can provide real-time testing with zero radiation exposure and low cost, making it more accessible to the general public and enabling earlier detection and treatment, thereby increasing the chances of successful recovery. The company aims to expand clinical trials within the next 2 years, with the goal of obtaining clinical certification for the lung cancer breath test instrument and making it available for use by healthcare institutions as soon as possible.